Livforsakringsbolaget Skandia Omsesidigt Invests $532,000 in Medpace Holdings, Inc. (NASDAQ:MEDP)

Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,600 shares of the company’s stock, valued at approximately $532,000.

Several other large investors have also recently added to or reduced their stakes in the company. Pallas Capital Advisors LLC raised its holdings in shares of Medpace by 179.7% during the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock worth $1,086,000 after purchasing an additional 2,101 shares during the period. Baillie Gifford & Co. grew its position in shares of Medpace by 175.6% during the 3rd quarter. Baillie Gifford & Co. now owns 14,876 shares of the company’s stock valued at $4,966,000 after buying an additional 9,478 shares during the last quarter. Barclays PLC raised its stake in Medpace by 71.9% during the third quarter. Barclays PLC now owns 19,781 shares of the company’s stock worth $6,603,000 after acquiring an additional 8,275 shares during the period. Oppenheimer Asset Management Inc. lifted its holdings in Medpace by 6.3% in the third quarter. Oppenheimer Asset Management Inc. now owns 45,473 shares of the company’s stock worth $15,179,000 after acquiring an additional 2,675 shares during the last quarter. Finally, CWA Asset Management Group LLC acquired a new position in Medpace in the third quarter valued at approximately $1,306,000. 77.98% of the stock is currently owned by institutional investors.

Medpace Trading Down 1.9 %

Medpace stock opened at $354.10 on Friday. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77. The stock has a market cap of $11.01 billion, a price-to-earnings ratio of 31.01, a PEG ratio of 1.79 and a beta of 1.36. The company’s 50-day moving average price is $343.61 and its two-hundred day moving average price is $350.38.

Analyst Ratings Changes

A number of analysts have recently weighed in on MEDP shares. Truist Financial dropped their price target on Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. Redburn Atlantic initiated coverage on Medpace in a research report on Monday, October 14th. They issued a “buy” rating and a $404.00 target price on the stock. Robert W. Baird boosted their price target on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Baird R W cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Finally, William Blair reiterated an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.